Abstract
PurposeWe aimed to conduct a meta-analysis to accurately evaluate the potential association between ADIPOQ rs2241766 gene SNP and breast cancer risk.MethodsA systematic literature search on Cochrane Library, PubMed, Embase, Web of Science and China National Knowledge Infrastructure (CNKI) identified 8 articles with 1692 cases and 1890 controls. Strength of association was evaluated by pooled odds ratio (OR), 95 % confidence interval (CI) and p value. Funnel plots and Begger’s regression test were applied for testing the publication bias. Statistical analysis of all data was performed by Stata 12.0.ResultsThe meta-analysis results indicated that the ADIPOQ rs2241766 gene polymorphism did not significantly associated with the risk of breast cancer for these genetic models (TT vs. TG + GG: OR = 1.20, 95 % CI = 0.77–1.89, p=0.417; TT + TG vs. GG: OR = 1.05, 95 % CI = 0.71–1.56, p=0.805; T vs. G: OR =1.17, 95 % CI = 0.79–1.74, p=0.437).ConclusionsThis study indicated that no significant relationship between the ADIPOQ rs2241766 SNP and breast cancer. Further large-scale and well-designed studies will be indispensable to confirm our result.
Highlights
Breast cancer was the most common malignant tumor in women, which was the second most common malignant tumor worldwide [1]
The meta-analysis results indicated that the ADIPOQ rs2241766 gene polymorphism did not significantly associated with the risk of breast cancer for these genetic models (TT vs. TG + GG: odds ratio (OR) = 1.20, 95 % confidence interval (CI) = 0.77–1.89, p=0.417; TT + TG vs. GG: OR = 1.05, 95 % CI = 0.71–1.56, p=0.805; T vs. G: OR =1.17, 95 % CI = 0.79–1.74, p=0.437)
This study indicated that no significant relationship between the ADIPOQ rs2241766 SNP and breast cancer
Summary
Breast cancer was the most common malignant tumor in women, which was the second most common malignant tumor worldwide [1]. Agency for Research on Cancer in 2012, a total of 1.67 million breast cancer patients were confirmed worldwide. This number accounted for 11.8 % of all tumors [2]. Previous studies on the relationship between the polymorphism of ADIPOQ rs2241766 gene and breast cancer susceptibility were limited and rather contradictory [10,11,12,13,14,15,16,17]. For lack of powerful evidence to provide a reliable conclusion in a single study, we conducted a comprehensive metaanalysis to assess the strength relationship between ADIPOQ rs2241766 gene polymorphism and breast cancer risk, which would have much greater possibility to reach reasonably reliable conclusions
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
